Is Immunotherapy Always a Last Resort?

To understand immunotherapy placement, start with the current reality: checkpoint inhibitors are no longer reserved for end-stage disease. For metastatic melanoma, many non-small cell lung cancers, renal cell carcinoma, and any MSI-H solid tumor, these drugs now sit at the front of the treatment plan, not the back. Pembrolizumab and nivolumab have earned first-line approvals based on trials showing better overall survival than older standards like ipilimumab or platinum chemotherapy alone.

Whether immunotherapy comes first, second, or later in your case depends on tumor biology, biomarker results, and a short list of clinical variables your oncologist weighs together.

This guide explains how sequencing actually works, which biomarkers drive the decision, the cancers where first-line use is standard, and the questions worth raising at your next oncology visit.

The Shift From Last-Resort to Frontline Therapy

For most of its early years, immunotherapy earned a reputation as the option you reached for after surgery, chemotherapy, and radiation had already run their course. That framing stuck because the earliest checkpoint inhibitor approvals came in metastatic melanoma, a setting where prior treatments had already failed. Oncologists learned these drugs as salvage tools, and many patients absorbed the same mental model.

The framing changed as trial evidence accumulated. Pembrolizumab and nivolumab both won first-line approvals in advanced melanoma based on studies showing better overall survival than ipilimumab. Non-small cell lung cancer followed, with pembrolizumab approved first-line when tumor PD-L1 expression crossed 50%. Renal cell carcinoma came next, where nivolumab plus ipilimumab replaced older targeted drugs as the preferred initial choice for intermediate- and poor-risk disease.

Why Guideline Bodies Updated Their Sequencing

Groups like the NCCN and ASCO revise their recommendations as new trial data lands. Over the past several years, those updates have repeatedly moved checkpoint inhibitors earlier in the sequence, sometimes replacing chemotherapy entirely and sometimes pairing with it. The pattern matters because oncologists often follow these guidelines when designing your plan, so what gets approved as first-line tends to show up in clinic visits soon after.

FDA approval timing and real-world prescribing do diverge slightly. A drug can carry a first-line indication while community oncologists still default to older regimens out of habit, familiarity, or insurance friction. Closing that gap is part of why patient education on sequencing has become more important for you.

Patient education only helps when the testing it relies on is actually completed, which is where biomarker workup reshapes the sequencing conversation.

How Biomarker Testing Drives Treatment Order

Biomarker testing is the single biggest factor that determines whether immunotherapy comes first, second, or later in your case. The tests look for molecular features on or inside tumor cells that predict response to checkpoint blockade, and each result maps to a specific sequencing decision.

The Practical Timeline for Biomarker Workup

Most comprehensive biomarker panels take two to four weeks from biopsy to result. That window shapes sequencing decisions in real time for you. An oncologist who suspects lung cancer will often order PD-L1 staining alongside the diagnostic biopsy so the first treatment discussion can include biomarker-informed options. Delays in testing, whether from insurance prior authorization or lab turnaround, can push immunotherapy later in your sequence even when the biology supports earlier use.

If your testing is incomplete before treatment starts, ask whether additional biomarker workup is reasonable before locking in a first regimen.

Solid testing opens the door, though only certain diagnoses currently translate that information into an upfront immunotherapy plan.

Cancers Where Immunotherapy Is Standard First-Line

Pembrolizumab, atezolizumab, and nivolumab now anchor the initial treatment regimens approved by the FDA for more than a dozen tumor types. The list grows each year, but a few core examples anchor current practice and may match your diagnosis.

• ▸Metastatic melanoma: Pembrolizumab or nivolumab monotherapy, sometimes combined with ipilimumab, is the preferred first-line option regardless of PD-L1 status.
• ▸Non-small cell lung cancer: Pembrolizumab alone for tumors with PD-L1 ≥ 50%, or pembrolizumab plus platinum chemotherapy for lower PD-L1 levels.
• ▸Renal cell carcinoma: Nivolumab plus ipilimumab for intermediate- and poor-risk disease, or pembrolizumab plus axitinib for broader risk categories.
• ▸Urothelial carcinoma: Atezolizumab and pembrolizumab are approved for cisplatin-ineligible patients with high PD-L1 expression.
• ▸MSI-H solid tumors: Pembrolizumab and dostarlimab are approved first-line for any unresectable or metastatic cancer showing microsatellite instability, regardless of where it started.

Adjuvant and Neoadjuvant Settings

Sequencing changes have not stopped at metastatic disease. Adjuvant immunotherapy, meaning treatment given after curative-intent surgery to reduce recurrence risk, is now approved in melanoma, non-small cell lung cancer, renal cell carcinoma, and several other cancers. Neoadjuvant immunotherapy, given before surgery to shrink tumors and improve surgical outcomes, has earned approvals in non-small cell lung cancer, triple-negative breast cancer, and bladder cancer.

These settings place immunotherapy firmly before any sign of recurrence, not after recurrence has been documented. That distinction matters because adjuvant and neoadjuvant use typically reflects the strongest curative-intent data, not a salvage strategy.

Where first-line immunotherapy is not standard, the same drugs often reappear later, and the timing depends on a handful of clinical and biologic variables.

When Immunotherapy Still Moves to Later Lines

Last-resort use has not vanished. Several clinical scenarios still push checkpoint inhibitors toward later lines of therapy, and recognizing where you fall on that spectrum helps you plan your questions.

Biomarker-Negative Tumors Without an Approved Indication

Some cancers lack a first-line checkpoint inhibitor indication when biomarkers are absent. Hepatocellular carcinoma, for example, has combination approvals (atezolizumab plus bevacizumab) that depend partly on tumor biology, and not every patient meets those criteria. In those cases, the standard first-line remains a tyrosine kinase inhibitor or locoregional therapy, and immunotherapy enters only if your disease progresses.

Refractory or Heavily Pretreated Disease

Patients whose cancers have already progressed through multiple regimens may still receive checkpoint inhibitors, but the framing is closer to a salvage attempt than a curative strategy. Response rates tend to be lower in heavily pretreated populations, and the bar for using these drugs weighs potential benefit against accumulated toxicity risk.

Performance Status and Comorbidities

Immunotherapy is generally better tolerated than cytotoxic chemotherapy, but it is not risk-free. Autoimmune toxicity, including colitis, pneumonitis, hepatitis, and endocrine disruption, can be severe and occasionally life-threatening. Patients with pre-existing autoimmune disease, poor performance status, or significant organ dysfunction may not be ideal candidates for early checkpoint blockade, even when biomarkers support it. In those situations, oncologists often choose alternative first-line options and revisit immunotherapy only if you stabilize.

Combination Regimens That Blur the Line

Many first-line regimens now pair immunotherapy with chemotherapy, which complicates the question of whether immunotherapy is truly first-line or simply riding alongside chemo. In non-small cell lung cancer, for instance, pembrolizumab plus carboplatin and pemetrexed is the standard first-line option for non-squamous histology regardless of PD-L1 status. You receive both drug classes from day one, and the sequencing question becomes less about immunotherapy alone and more about the combination regimen as a unit.

Factors Oncologists Weigh Before Choosing Timing

The decision to use immunotherapy early or late depends on a small set of variables that your oncologist evaluates together rather than in isolation.

• ▸Cancer type and histology: Some tumor types have robust first-line immunotherapy data; others do not.
• ▸Stage at diagnosis: Locoregional disease may support adjuvant or neoadjuvant use, while metastatic disease shifts the conversation toward systemic first-line options.
• ▸Biomarker status: PD-L1, MSI-H, dMMR, and TMB results guide whether checkpoint inhibitors are likely to work early.
• ▸Prior therapy exposure: Patients who already received certain chemotherapies or targeted drugs may have altered tumor biology.
• ▸Performance status and organ function: Fitness for treatment-related toxicity matters, especially in older adults.
• ▸Cost and infusion access: Immunotherapy is expensive, infusion schedules are demanding, and insurance coverage varies.
• ▸Clinical trial availability: Trials sometimes offer checkpoint inhibitor combinations not yet approved, which can shift sequencing decisions.

“Cost and access realities influence sequencing even when guidelines support earlier use. If your plan involves a checkpoint inhibitor, confirm infusion scheduling, prior authorization timelines, and out-of-pocket estimates before committing to a specific regimen.

Cost, Coverage, and Access

Checkpoint inhibitors list at tens of thousands of dollars per infusion cycle. Most insured patients pay a fraction of that through copay assistance programs, but coverage gaps, high-deductible plans, and Medicare Part B coinsurance can create real barriers for you. Infusion logistics matter too: many checkpoint inhibitors require day-long visits every three to six weeks, and travel to a certified infusion center can strain patients in rural areas.

These practical realities sometimes delay immunotherapy even when guidelines say it should come first.

Clinical Trial Pathways

Trial enrollment can move immunotherapy earlier in your sequence, particularly for cancers without a clear first-line standard. Many academic centers now run first-line checkpoint inhibitor studies that offer access to combinations years before FDA approval. Ask your oncologist whether a relevant trial exists for your specific diagnosis and biomarker profile.

Asking the Right Questions About Your Treatment Sequence

Treatment sequencing is negotiable in the sense that you can always ask why a particular order was chosen. The most useful conversations happen before a regimen starts, not after it fails.

Specific Biomarker Results Worth Requesting

Ask for a copy of your pathology report and biomarker testing results. Key items to look for include PD-L1 TPS or CPS, MSI or MMR status, and TMB if performed. Each value carries a threshold that can change your sequencing: a PD-L1 TPS of 49% versus 51% is the difference between chemo-immunotherapy combination and monotherapy in non-small cell lung cancer. Knowing your exact numbers helps you evaluate whether your plan reflects current evidence.

Second Opinions and Molecular Tumor Boards

If your oncologist frames immunotherapy as a last-resort option and your biomarkers suggest otherwise, a second opinion at an academic center or NCI-designated cancer center is reasonable. Many institutions run molecular tumor boards where specialists review complex cases and recommend sequencing. That review is especially valuable for rare cancers or unusual biomarker patterns where community guidelines may not apply directly to you.

Language for Discussing Adjuvant or Neoadjuvant Timing

If surgery is planned, ask specifically whether adjuvant or neoadjuvant immunotherapy is appropriate for your cancer type and stage. Phrases like “Has adjuvant pembrolizumab been considered for my stage III disease?” or “Is there a neoadjuvant checkpoint inhibitor trial for my tumor type?” signal that you understand the difference between perioperative and later-line use. Your oncologist should welcome those questions; if they do not, that is itself useful information for you.

Signs That a Sequencing Plan Reflects Evidence, Not Habit

Plans grounded in current evidence typically cite specific trials, biomarker thresholds, and guideline versions. Plans driven by habit often default to older chemotherapy regimens without explaining why immunotherapy was deferred, or they apply first-line immunotherapy in settings where biomarker data would predict poor response. A reasonable oncologist can articulate the reasoning behind sequencing in plain language. When the answer is vague, ask for the guideline reference.

The Bottom Line

Immunotherapy sequencing is not a fixed sequence at all. It is a decision framework built on tumor biology, biomarker results, cancer type, and patient fitness, all of which your oncologist weighs before choosing first-line, second-line, or later use. The old mental model of “save it for last” describes a narrow set of refractory cases, not the modern landscape.

Knowing your biomarkers, asking about guideline-supported options, and pushing for clarity on sequencing logic are the most productive steps you can take at your next visit.

FAQ